LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

MacroGenics Inc

Отворен

СекторЗдравеопазване

1.55 5.44

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.44

Максимум

1.55

Ключови измерители

By Trading Economics

Приходи

-26M

-41M

Продажби

-4.5M

13M

P/E

Средно за сектора

38.83

54.533

EPS

-0.65

Марж на печалбата

-311.067

Служители

341

EBITDA

-30M

-43M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+167.52% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-53M

100M

Предишно отваряне

-3.89

Предишно затваряне

1.55

Настроения в новините

By Acuity

50%

50%

187 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2025 г., 23:25 ч. UTC

Горещи акции

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21.05.2025 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21.05.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefónica's Operations in Uruguay

21.05.2025 г., 21:01 ч. UTC

Значими двигатели на пазара

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21.05.2025 г., 23:49 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21.05.2025 г., 23:37 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21.05.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21.05.2025 г., 23:32 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21.05.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21.05.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21.05.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21.05.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21.05.2025 г., 23:28 ч. UTC

Печалби

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21.05.2025 г., 23:27 ч. UTC

Печалби

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21.05.2025 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21.05.2025 г., 23:22 ч. UTC

Топ новини

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21.05.2025 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21.05.2025 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21.05.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21.05.2025 г., 23:04 ч. UTC

Топ новини

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21.05.2025 г., 21:46 ч. UTC

Топ новини

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21.05.2025 г., 21:42 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21.05.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefónica's Ops in Uruguay

21.05.2025 г., 21:07 ч. UTC

Топ новини

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21.05.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

167.52% нагоре

12-месечна прогноза

Среден 4.2 USD  167.52%

Висок 8 USD

Нисък 2 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

8 ratings

2

Купи

6

Задържане

0

Продай

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

187 / 382 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.